Abbott Laboratories
NYSESnapshot as of 8 May 2026
A new long-form analysis for ABT this week — anomalies vs the company's own history, peer comparisons, news context, and the full data picture. Premium subscribers only.
Read on ORTEX →Sign up for premiumABT heads into the back half of April with insiders putting money to work at a stock that has fallen nearly 26% year-to-date — even as a wave of analyst target cuts follows the company's Q1 earnings miss. The most…
Short interest updated daily, real-time options flow, analyst consensus deltas, 13F positioning, ORTEX Alpha signals, and every article ORTEX publishes for ABT — free to start on ORTEX.
